165 related articles for article (PubMed ID: 25441685)
1. Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor.
Hu Y; Bobb D; Lu Y; He J; Dome JS
Cancer Genet; 2014 Sep; 207(9):403-11. PubMed ID: 25441685
[TBL] [Abstract][Full Text] [Related]
2. The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma.
Hu Y; Bobb D; He J; Hill DA; Dome JS
Cancer Biol Ther; 2015; 16(6):949-57. PubMed ID: 25920748
[TBL] [Abstract][Full Text] [Related]
3. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.
Frink RE; Peyton M; Schiller JH; Gazdar AF; Shay JW; Minna JD
Oncotarget; 2016 May; 7(22):31639-51. PubMed ID: 27192120
[TBL] [Abstract][Full Text] [Related]
4. Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks.
Wu X; Smavadati S; Nordfjäll K; Karlsson K; Qvarnström F; Simonsson M; Bergqvist M; Gryaznov S; Ekman S; Paulsson-Karlsson Y
Biochim Biophys Acta; 2012 Dec; 1823(12):2130-5. PubMed ID: 22906540
[TBL] [Abstract][Full Text] [Related]
5. The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
Koziel JE; Herbert BS
Breast Cancer Res Treat; 2015 Feb; 149(3):607-18. PubMed ID: 25627551
[TBL] [Abstract][Full Text] [Related]
6. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines.
Joseph I; Tressler R; Bassett E; Harley C; Buseman CM; Pattamatta P; Wright WE; Shay JW; Go NF
Cancer Res; 2010 Nov; 70(22):9494-504. PubMed ID: 21062983
[TBL] [Abstract][Full Text] [Related]
7. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth.
Marian CO; Cho SK; McEllin BM; Maher EA; Hatanpaa KJ; Madden CJ; Mickey BE; Wright WE; Shay JW; Bachoo RM
Clin Cancer Res; 2010 Jan; 16(1):154-63. PubMed ID: 20048334
[TBL] [Abstract][Full Text] [Related]
8. Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma.
Wu X; Zhang J; Yang S; Kuang Z; Tan G; Yang G; Wei Q; Guo Z
Oncotarget; 2017 Feb; 8(8):13600-13619. PubMed ID: 28099140
[TBL] [Abstract][Full Text] [Related]
9. BIBR1532, a Selective Telomerase Inhibitor, Enhances Radiosensitivity of Non-Small Cell Lung Cancer Through Increasing Telomere Dysfunction and ATM/CHK1 Inhibition.
Ding X; Cheng J; Pang Q; Wei X; Zhang X; Wang P; Yuan Z; Qian D
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):861-874. PubMed ID: 31419512
[TBL] [Abstract][Full Text] [Related]
10. Imetelstat (a telomerase antagonist) exerts off‑target effects on the cytoskeleton.
Mender I; Senturk S; Ozgunes N; Akcali KC; Kletsas D; Gryaznov S; Can A; Shay JW; Dikmen ZG
Int J Oncol; 2013 May; 42(5):1709-15. PubMed ID: 23545855
[TBL] [Abstract][Full Text] [Related]
11. Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells.
Barszczyk M; Buczkowicz P; Castelo-Branco P; Mack SC; Ramaswamy V; Mangerel J; Agnihotri S; Remke M; Golbourn B; Pajovic S; Elizabeth C; Yu M; Luu B; Morrison A; Adamski J; Nethery-Brokx K; Li XN; Van Meter T; Dirks PB; Rutka JT; Taylor MD; Tabori U; Hawkins C
Acta Neuropathol; 2014 Dec; 128(6):863-77. PubMed ID: 25120190
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer.
Chiappori AA; Kolevska T; Spigel DR; Hager S; Rarick M; Gadgeel S; Blais N; Von Pawel J; Hart L; Reck M; Bassett E; Burington B; Schiller JH
Ann Oncol; 2015 Feb; 26(2):354-62. PubMed ID: 25467017
[TBL] [Abstract][Full Text] [Related]
13. MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.
Howard TP; Arnoff TE; Song MR; Giacomelli AO; Wang X; Hong AL; Dharia NV; Wang S; Vazquez F; Pham MT; Morgan AM; Wachter F; Bird GH; Kugener G; Oberlick EM; Rees MG; Tiv HL; Hwang JH; Walsh KH; Cook A; Krill-Burger JM; Tsherniak A; Gokhale PC; Park PJ; Stegmaier K; Walensky LD; Hahn WC; Roberts CWM
Cancer Res; 2019 May; 79(9):2404-2414. PubMed ID: 30755442
[TBL] [Abstract][Full Text] [Related]
14. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma.
Djojosubroto MW; Chin AC; Go N; Schaetzlein S; Manns MP; Gryaznov S; Harley CB; Rudolph KL
Hepatology; 2005 Nov; 42(5):1127-36. PubMed ID: 16114043
[TBL] [Abstract][Full Text] [Related]
15. Telomerase inhibitor Imetelstat (GRN163L) limits the lifespan of human pancreatic cancer cells.
Burchett KM; Yan Y; Ouellette MM
PLoS One; 2014; 9(1):e85155. PubMed ID: 24409321
[TBL] [Abstract][Full Text] [Related]
16. Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis.
Mosoyan G; Kraus T; Ye F; Eng K; Crispino JD; Hoffman R; Iancu-Rubin C
Leukemia; 2017 Nov; 31(11):2458-2467. PubMed ID: 28270692
[TBL] [Abstract][Full Text] [Related]
17. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study.
Salloum R; Hummel TR; Kumar SS; Dorris K; Li S; Lin T; Daryani VM; Stewart CF; Miles L; Poussaint TY; Stevenson C; Goldman S; Dhall G; Packer R; Fisher P; Pollack IF; Fouladi M; Boyett J; Drissi R
J Neurooncol; 2016 Sep; 129(3):443-451. PubMed ID: 27350411
[TBL] [Abstract][Full Text] [Related]
18. Telomerase inhibitors: a patent review (2010-2015).
Man RJ; Chen LW; Zhu HL
Expert Opin Ther Pat; 2016 Jun; 26(6):679-88. PubMed ID: 27104627
[TBL] [Abstract][Full Text] [Related]
19. Pathology and diagnosis of SMARCB1-deficient tumors.
Margol AS; Judkins AR
Cancer Genet; 2014 Sep; 207(9):358-64. PubMed ID: 25246033
[TBL] [Abstract][Full Text] [Related]
20. Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis.
Darr J; Klochendler A; Isaac S; Eden A
Oncogene; 2014 Jun; 33(23):3024-32. PubMed ID: 23851500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
